About Fractyl Health

About Fractyl Health

Addressing root causes of metabolic disease—in the gut

Fractyl Health is an organ editing metabolic therapeutics company pioneering a new approach to the treatment of type 2 diabetes (T2D). Our goal is to transform treatment from chronic blood glucose management to disease-modifying therapies that target the organ-level root causes of T2D.

We have assembled a mission-driven team of innovators, united in a passion to eradicate T2D and to develop breakthrough therapies—the type of therapies we would want for ourselves, our family members, and our loved ones with the disease.

Our approach involves identifying diseased metabolic organs at the root of the T2D disease process and designing disease-modifying treatments that aim to reverse the core pathology in these organs that is driving the disease process. We believe that addressing the diseased organs in a manner that is designed to restore their metabolic health and function offers the potential for disease eradication in a manner that current approaches, focused on lifestyle intervention or pharmacological management, have not been able to achieve. We call this approach “organ editing.”

Leadership

We are experts in metabolic disease.

Management Team

Harith Rajagopalan, MD, PhD Open

Harith Rajagopalan, MD, PhD

Co-founder and CEO

Jay Caplan Open

Jay Caplan

Co-founder and President

Lisa Davidson Open

Lisa Davidson

Chief Financial Officer

Juan Carlos Lopez-Talavera, MD, PhD Open

Juan Carlos Lopez-Talavera, MD, PhD

Chief Medical Officer

Sarah Toomey Open

Sarah Toomey

General Counsel and Corporate Secretary

Jon Fitzgerald Open

Jon Fitzgerald

Vice President of Quality Assurance and Regulatory Affairs

Len Rosberg Open

Len Rosberg

Vice President of Manufacturing

Kelly White, PharmD Open

Kelly White, PharmD

Vice President of Clinical and Medical Affairs

Roya Salamipour Open

Roya Salamipour

Vice President of Human Resources

You are now leaving the Fractyl.com website

You are leaving Fractyl’s main website to go to Fractyl’s U.K. site.

By selecting Continue you will be directed to Fractyl’s U.K. site. If you would like to remain on Fractyl’s main site, select the Cancel button.

ContinueCancel